Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.
MATR Foods is a food-tech startup that provides fungi-based food ingredients.
Cleveland Diagnostics is a diagnostics company developing efficacious, affordable diagnostics tests to improve cancer diagnostics.
LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.
Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.
KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME).
Nalu Medical is a medical technology company that offers neurostimulation system designed to treat chronic nerve pain.
Phasecraft develops quantum algorithms and related intellectual property for scientific and industrial applications.
BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3Kα malignancies.
Mission Bio develops only single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development.
MapLight Therapeutics is a biopharma company that offers a platform designed to discover and develop therapeutics for brain disorders.
MedGenome develops a genomics-based diagnostics and research solution for healthcare providers to understand the genetic basis of diseases.
Based on our deep science and focused on patients in need.
Tempus develops AI-enabled precision medicine technology that supports clinical decision-making and biomedical research.
GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.
Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
Glycomine is an early-stage biotech working on replacement therapies for rare diseases.
HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
AgNext is working at the intersection of hardware, software and analytics for quality estimation in agriculture and food.
Tribune Therapeutics specializes in building promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions.
Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.
Augustine Therapeutics is discovering and developing innovative medicines for the treatment of neuromuscular and neurodegeneratives diseases
Novo Holdings has invested in 216 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novo Holdings's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 27 different industry categories.
Among tracked funding rounds, Tempus received $650.0M in a Post Ipo Debt round. Novo Holdings's total known invested capital is $15.2B.
Novo Holdings's average investment size is $84.4M across its portfolio of 216 companies.
Recent Novo Holdings portfolio additions include Hemab, MATR Foods, Cleveland Diagnostics, LEXEO Therapeutics, Expedition Therapeutics. These companies were founded in 2020 or later.